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G domains of the mouse laminin a1 and a4 chains
consisting of its five subdomains LG1–LG5 were overex-
pressed in Chinese hamster ovary cells and purified by
heparin chromatography. a1LG1–LG5 and a4LG1–LG5
eluted at NaCl concentrations of 0.30 and 0.47 M, respec-
tively. In solid phase binding assays with immobilized
heparin, half-maximal concentrations of 14 (a1LG1–
LG5) and 1.4 nM (a4LG1–LG5) were observed. N-Glycan
cleavage of a4LG1–LG5 did not affect affinity to heparin.
The affinity of a4LG1–LG5 was significantly reduced
upon denaturation with 8 M urea but could be recovered
by removing urea. Chymotrypsin digestion of a4LG1–
LG5 yielded high and low heparin affinity fragments
containing either the a4LG4–LG5 or a4LG2–LG3 mod-
ules, respectively. Trypsin digestion of heparin-bound
a4LG1–LG5 yielded a high affinity fragment of about 190
residues corresponding to the a4LG4 module indicating
that the high affinity binding site is contained within
a4LG4. Competition for heparin binding of synthetic
peptides covering the a4LG4 region with complete
a4LG1–LG5 suggests that the sequence AHGRL1521 is
crucial for high affinity binding. Introduction of muta-
tion of H1518A or R1520A in glutathione S-transferase
fusion protein of the a4LG4 module produced in Esche-
richia coli markedly reduced heparin binding activity of
the wild type. When compared with the known structure
of a2LG5, this sequence corresponds to the turn con-
necting strands E and F of the 14-stranded b-sheet sand-
wich, which is opposite to the proposed binding sites for
calcium ion, a-dystroglycan, and heparan sulfate.
Basement membranes are sheet-like extracellular matrices
underlying epithelial and endothelial cells, surrounding muscle
cells, adipocytes, and peripheral nerve axons, and acting as
supportive architecture for the cells to proliferate, differenti-
ate, and migrate. These matrices contain one or more members
of the laminin family as a major component. The laminins
consist of heterotrimeric (abg) glycoproteins, and five a, three
b, and three g subchains have been recognized to combine into
more than 11 heterotrimeric molecules identified so far (1–7).
The best characterized laminin-1 (a1b1g1) is a cross-shaped
molecule in which all three chains contribute to the a-helical
coiled-coil to form the long arm of the cross, whereas the short
arms are composed of one chain each (8). Since the N-terminal
short arm region is truncated in a3 (splice variant of a3A), a4,
b3, and g2, we can define three groups of laminins; the cross-
shaped laminins containing a complete complement of domains
(laminins-1, -2, -3, -4, -10, and -11), the rod-shaped laminins
lacking domains in all three short arms (laminin-5), and the
Y-shaped laminins lacking an a chain short arm but remaining
full-sized b and g chains (laminins-6, -7, -8, and -9). Laminin-1,
-2, and -4 form polymers by reversible self-assembly of mono-
mers at short arms in a calcium ion- and temperature-depend-
ent manner with a critical concentration of assembly of 70–140
nM (9–11). This polymerization of the cross-shaped laminins
has a central role in forming the meshwork architecture of
basement membranes. Since all three short arms are required
for self-assembly (11), the laminins lacking either of three short
arms cannot contribute to the architecture.
Compared with b and g chains, all a chains are unique in
that their C termini contain a tandem of five laminin G-like
(LG)1 modules, which form a large globular structure at the
C-terminal end of laminins and contains binding sites for hep-
arin (12) and a-dystroglycan (13, 14). Taking advantage of
recombinant G domain overexpressed in cultured cell lines,
their functional regions have been characterized for a1, a2, and
a5 (15–21). Recent crystallography of the mouse a2LG5 re-
vealed a 14-stranded b-sheet sandwich structure, in which a
calcium ion-binding site is mapped at one edge of the sandwich
surrounded by the residues implicated in heparin and a-dys-
troglycan binding (22). Crystal structure of the a2LG4–LG5
pair showed that they are arranged in a V-shaped fashion
related by a 110° rotation to locate two calcium ion-binding
sites 65 Å apart at the tips of the domains opposite the polypep-
tide termini where they have contacting interface (23).
Laminin a4 lacks the N-terminal short arm and shows an
expression pattern distinct from that of the full size a chains. It
is expressed in the cell of mesenchymal origin such as endo-
thelial cells (24–27) and mouse 3T3-L1 adipocytes (28, 29).
Studies on developing mice showed a4 mRNA to be detectable
at embryonic day 7 and peaked at day 15 (30). In adult tissues,
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the expression was localized mainly in mesenchymal cells of
lung, cardiac, and skeletal muscle fibers, and immunohistology
detected laminin a4 antigen in capillary basement membranes
as well as perineurium (30).
Since truncation of N-terminal short arm and characteristic
expression patterns suggest distinct activity of the a4 G do-
main from those of a1 and a2, we have overexpressed mouse
a4LG1–LG5 in dhfr-deficient CHO cells and compared its hep-
arin binding activity with that of a1LG1–LG5 overexpressed in
parallel. We report here that a4LG1–LG5 has stronger affinity
to heparin than a1LG1–LG5. While the region spanning a4
LG2–LG3 had affinity comparable to a1LGs, a4LG4 was found
to be responsible for the strong binging to heparin.
MATERIALS AND METHODS
Plasmid Construction—Plasmids for the expression of recombinant
mouse laminin a1LG1–LG5 and a4LG1–LG5 (Fig. 1) were constructed
based on the pEF series of plasmids (31, 32) which have laminin chain
cDNA sequences inserted between the signal sequence of erythropoietin
receptor for the delivery of the products to the secretory pathway and a
c-Myc sequence for epitope tagging. For pEFa4Gmyc, mouse laminin
a4cDNA clones isolated from a mouse heart cDNA library constructed
in lZAPII (Stratagene) were used. These included pA4-3 (covering the
1.4-kb fragment between nt 4261 and poly(A) tail; nucleotide numbers
according Ref. 33), pA4-8 (1.4 kb, nt 3658–5021), pA4–14 (1.9 kb, nt
2714–4611), and pA4–15 (2.5 kb, nt 840–3315). The 0.7-kb EcoRI-XbaI
fragment of pA4-8 and the 1.4-kb SacI-EcoRI fragment of pA4-14 were
connected at the EcoRI end and subcloned in SacI and XbaI sites of
pBluescript SK1 to generate pBSA4Sac/Xba. A cDNA fragment corre-
sponding to nt 4954–5445 was prepared by PCR using pA4-3 as tem-
plate and a reverse primer tagged with an extra 59 EcoRV sequence.
The resulting fragment was digested with XbaI and EcoRV, and sub-
cloned into XbaI and EcoRV sites of pBSA4Sac/Xba to yield pBSA4Sac/
EcoRV. A cDNA fragment nt 2497–2758t was prepared by PCR using
pA4–15 as template and a forward primer tagged with an extra 59 SmaI
sequence. The resulting fragment was connected to the SacI-EcoRV
fragment in pBSA4Sac-EcoRV after digestion with SmaI and SacI and
inserted to SmaI and EcoRV sites of the pEFDb1S to generate
pEFa4Gmyc. The sequence was confirmed to code for the mouse
a4LG1–LG5 sequence from Gly833 to Ala1815 followed by a Myc-tag
sequence. For construction of pEFa1Gmyc, a cDNA fragment coding for
the mouse laminin a1 sequence (34) from Ile2100 to Pro3060 was prepared
by RT-PCR using total RNA extracted from mouse embryonal carci-
noma F9 cells and forward and reverse primers tagged with extra 59
BamHI and EcoRV sequences, respectively. The laminin b1 fragment in
pEFEDb1S was replaced by this fragment at BamHI and EcoRV sites to
generate pEFa1Gmyc.
a4LG4 module was expressed also in Escherichia coli as a GST fusion
protein. For this, a cDNA fragment corresponding to nt 4357–4908 was
prepared by PCR of pEFa4myc using a forward primer tagged with an
extra 59 BamHI sequence and a reverse primer tagged with an extra 59
EcoRI sequence. The amplified fragment was digested with BamHI and
EcoRI and inserted into corresponding sites of pGEX-2T (Amersham
Pharmacia Biotech). Site-directed mutagenesis was accomplished with
Quick Change Site-directed Mutagenesis Kit (Stratagene). For H1518A
mutation, paired primers of 59-CTGTTCTTGGCCGCGGGTCGCTTGG-
TC-39 and 59-GACCAAGCGACCCGCGGCCAAGAACAG-39 were used.
For R1520A mutation, paired primers of 59-CCTGTTCTTGGCCCATG-
GTGCGTTGGTCTTTATGTTTAATG-39 and 59-CATTAAACATAAAGA-
CCAACGCACCATGGGCCAAGAACAGG-39 were used.
Cell Culture—dhfr-deficient CHO DG44 cells (provided by Dr. Law-
rence Chasin, Columbia University, New York) were used for overex-
pression of mouse a1LG1–LG5 and a4LG1–LG5 domains. Cells were
maintained in a-minimal essential medium containing nucleosides and
deoxynucleosides, and supplemented with 10% fetal calf serum and
antibiotics. Once the stable transfectants were established, a-minimal
essential medium without nucleosides and deoxynucleosides was used.
To check for N-glycosylation of G domains, cells were allowed to attach
to culture dishes, washed with Dulbecco’s modified PBS, and fed with
fresh medium containing 10 mg/ml tunicamycin. After 12 h, cell lysates
and conditioned media were analyzed by immunoblot using antiserum
against c-Myc (Santa Cruz Biotechnology, sc-789).
DNA Transfection and Selection for Stable Transfectants—Cells were
transfected with the plasmids together with pGEMSVdhfr encoding a
DHFR minigene (provided by Dr. Hiroshi Teraoka, Shionogi Research
Laboratory, Osaka, Japan) by calcium-phosphate precipitation. Selec-
tion for stable transfectants and subsequent amplification of the intro-
duced cDNA were carried out as described (35). Expression levels of
recombinant G domains were monitored by dot immunoassay of condi-
tioned media with antiserum against c-Myc.
Purification of a1 and a4 G Domains—Conditioned medium (about
500 ml each) of a1LG1–LG5 or a4LG1–LG5 expressing cells was har-
vested and centrifuged at 1000 3 g for 10 min to remove cell debris. The
supernatant was adjusted to 0.5 mM N-ethylmaleimide, and applied to
a 5-ml heparin affinity column (HiTrap, Amersham Pharmacia Biotech;
3 ml/min) equilibrated in 10 mM Tris-Cl (pH 7.4), 150 mM NaCl, 2 mM
EDTA, 0.5 mM N-ethylmaleimide (buffer A). For efficient binding, the
flow-through was recycled about 5 times. Elution was carried out on a
FPLC system (Amersham Pharmacia Biotech). The column was washed
with 30 ml of buffer A, eluted at 0.5 ml/min with a 150-ml linear
gradient of 150 to 600 mM NaCl in buffer A, and 2.5-ml fractions were
collected. Protein concentration in the fractions was determined with
the BCA assay (Pierce) with BSA as standard. Purity and amount of
recombinant protein was monitored by SDS-gel electrophoresis in 8%
acrylamide gels under reducing conditions (20-ml aliquots). Pure frac-
tions were combined, concentrated up to 0.4 mg/ml, and desalted using
Centriprep-30 concentrators (Amicon). 500 ml of medium yielded about
3 mg of purified a1LG1–LG5 or a4LG1–LG5.
Urea De- and Renaturation of a4LG1–LG5 Bound to Heparin—Three
1-ml HiTrap heparin columns A, B, and C were equilibrated with 10 mM
Tris-Cl (pH 7.4), 2 mM EDTA (buffer B) and loaded with 0.3 mg each of
purified a4LG1–LG5. After washing with 3 ml of buffer B, column A
was further washed with 3 ml of buffer B while the others were washed
with 3 ml of buffer B containing 8 M urea. Columns A and C were then
washed with 3 ml of buffer B while column B was washed with 3 ml of
buffer B containing 8 M urea. Elution was performed on a FPLC system
(0.1 ml/min) with a 30-ml linear gradient from 0 to 800 mM NaCl in
buffer B for columns A and C, and in 8 M urea containing buffer B for
column B. Proteins of 1-ml fractions were precipitated by 10% (w/v)
trichloroacetic acid, pellets were washed with acetone, and dissolved in
SDS sample buffer.
Proteolytic Fragmentation of a4LG1–LG5—Purified a4LG1–LG5 (1.2
mg) was digested at 37 °C with 1-chloro-3-tosylamido-7-amino-2-hep-
tanone-treated a-chymotrypsin (Sigma C-3142) or L-1-tosylamido-2-
phenylethyl chloromethyl ketone-treated trypsin (Sigma T-8642) at a
1:50 enzyme/substrate ratio for 2 h. Digestion was stopped by addition
of phenylmethylsulfonyl fluoride to a final concentration of 1 mM. The
digest was applied to a 1-ml Hi-trap heparin column. The column was
washed with 6 ml of buffer A, bound protein was eluted on a FPLC
system with a 30-ml linear gradient from 150 to 700 mM NaCl in buffer
A, and 1-ml fractions were collected. For SDS-gel electrophoresis, frac-
tions were precipitated with trichloroacetic acid as described above.
Alternatively, digestion with trypsin was carried out after binding to
a heparin column. Purified a4LG1–LG5 (0.4 mg) was bound to a 1-ml
heparin column, and 15 mg of trypsin dissolved in 1 ml of 50 mM Tris-Cl
(pH 7.4), 100 mM NaCl, 2 mM CaCl2 was applied to the column. The
column was incubated for 2 h at 37 °C and connected to a FPLC system.
After washing with 6 ml of buffer A, the column was eluted (0.1 ml/min)
with a 25-ml linear gradient from 150 to 600 mM NaCl in buffer A, and
1-ml fractions were collected. For Tricine-gel electrophoresis, fractions
were precipitated with trichloroacetic acid as described.
Microsequencing of Proteolytic Fragments—After electrophoresis,
separated peptides were transferred onto polyvinylidene difluoride
membranes and stained with Coomassie Brilliant Blue G-250. Corre-
sponding parts of the membrane were cut out, and the peptides were
sequenced from the N terminus (36).
Digestion with PNGase F—N-Glycans of a4LG1–LG5 were cleaved
with PNGase F (BioLabs) according to the manufacturer’s instructions.
15 ml of enzyme solution and 30 ml of 3 10 G7 buffer (500 mM sodium
phosphate buffer, pH 7.5) were added to purified protein (75 mg in 250
ml) and incubated at 37 °C overnight. As a control, 15 ml of water
instead of the enzyme solution was used on a separate sample. After
appropriate dilution, the digest was directly used for immunoblot and
heparin binding analysis.
a1LG1–LG5 and a4LG1–LG5 Binding to Solid-phase Heparin—Sol-
id-phase assays were carried out as described with slight modification
(37). Multiwell plates (96 wells; Nunc) were incubated with 10 mg/ml
heparin-BSA (Sigma) in 15 mM Na2CO3, 35 mM NaHCO3 (pH 9.2), and
3 mM NaN3 as the first ligand for 18 h at 4 °C. Wells were then blocked
with 1% (w/v) BSA in 50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 5 mM CaCl2
(blocking buffer) at room temperature for 2 h. After washing five times
with 0.04% Tween 20 in PBS (10 mM Na2HPO4, 2 mM K2HPO4, 140 mM
NaCl, and 3 mM KCl; washing buffer), wells were incubated with
a1LG1–LG5 or a4LG1–LG5 serially diluted with blocking buffer as the
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second ligand. After incubation for 2 h at 4 °C, wells were washed five
times with washing buffer, and the bound G domain was incubated with
antiserum against a1LG1–LG5, a4LG1–LG5, or c-Myc with dilutions of
1:1000, 1:1000, or 1:400, respectively. After washing five times with
washing buffer, bound antibodies were detected with horseradish per-
oxidase-conjugated goat anti-rabbit IgG (Amersham Pharmacia Bio-
tech) followed by addition of 0.4 mg/ml o-phenylenediamine dihydro-
chloride (Sigma) dissolved in 50 mM phosphate citrate buffer and 0.01%
H2O2. The reaction was stopped with 3 M HCl. Color yields were deter-
mined at 492 nm in a Microplate Reader (Bio-Rad, Model 3550-UV).
Competition Assay of Synthetic Peptides with a4LG1–LG5 for Hepa-
rin Binding—One-hundred and 16 peptides (A4G1–116) covering
a4LG1–LG5 were designed according to the deduced amino acid se-
quenced in Ref. 33. Twenty-four peptides (A4G74–97) corresponding to
a4LG4 module and two control peptides (A4G82S and A4G82T) were
synthesized by the 9-fluorenylmethoxycarbonyl (Fmoc) strategy and
purified by high performance liquid chromatography as described pre-
viously (38). Purity and identity of the peptides were confirmed by an
analytical high performance liquid chromatography and an ion spray
mass spectrometer, respectively. Either of the synthetic peptides (21
mg), a4LG1–LG5 (3.4 mg) and heparin-Sepharose CL-6B beads (1 mg)
were mixed in 70 ml of 10 mM Tris-Cl (pH 7.4), 100 mM NaCl. After
incubation for 1 h at 4 °C, the mixture was loaded on an open column.
Beads were flashed three times with 100 ml of the same buffer. Bound
protein was extracted with SDS sample buffer and analyzed by SDS-gel
electrophoresis.
Heparin Binding Assay of the Mutants of a4LG4 Module—GST fu-
sion proteins of a4LG4 module and the mutants were extracted from E.
coli by sonication in a buffer containing 10 mM Tris-HCl (pH 7.4) and 2
mM EDTA. The extract (5 ml) was applied to a heparin-Sepharose
CL-6B column of 0.5 ml equilibrated with the same buffer. For efficient
binding, the flow-through fraction was reloaded three times. The col-
umn was washed with 5 ml of the buffer and eluted with 5 ml each of the
buffer containing 100, 200, 400, 500, 600, and 1000 mM NaCl. 10 ml of
the fractions was analyzed by immunoblot.
Gel Electrophoresis and Immunoblot Analysis—SDS-gel electro-
phoresis was performed using 8 or 12% acrylamide gels as described
(39). Gels were stained with Coomassie Brilliant Blue R-250. Samples
were dissolved in SDS sample buffer with or without 2% (v/v) 2-mer-
captoethanol. Tricine-gel electrophoresis was carried out as described
(40) followed by staining with Coomassie Brilliant Blue G-250. For
immunoblot analysis, proteins were transferred to Hybond ECL nitro-
cellulose membrane (Amersham Pharmacia Biotech) and the mem-
brane was blocked with 5% (w/v) skim milk in PBS (immunoblot block-
ing buffer) at room temperature for 2 h. After washing five times with
0.1% Tween 20 in PBS (immunoblot washing buffer), the membrane
was incubated at room temperature for 2 h with antiserum against
a1LG1–LG5, a4LG5, synthetic peptide having the sequence in a4LG5,
c-Myc, or GST diluted in immunoblot blocking buffer 1:1000 or 1:400 as
the first antibody. After further washing, the membrane was incubated
at room temperature for 1 h with horseradish peroxidase-conjugated
donkey anti-rabbit IgG (Amersham Pharmacia Biotech) diluted in im-
munoblot blocking buffer to 1:1000 as the second antibody. ECL West-
ern blotting detection reagents (Amersham Pharmacia Biotech) were
used for developing.
Antisera—Antisera against a4LG1–LG5, a4LG1–LG5, and GST
were raised by injecting the purified proteins into rabbits. Antiserum
against a synthetic peptide LDESFNIGLKFEI (residues 1652–1665 of
mouse a4) was raised as described (29).
RESULTS
Overexpression of Mouse a4LG1–LG5 and a4LG1–LG5—
dhfr-deficient CHO cells were transfected with plasmids encod-
ing the G domains of mouse laminin a1 (a1LG1–LG5) and a4
(a4LG1–LG5) chains, respectively, together with a dhfr mini-
gene (pGEMSVdhfr) (Fig. 1). Cells overexpressing and secret-
ing the G domains into the medium were selected among the
clones resistant to increasing concentrations of methotrexate
by dot-blot immunoassay using anti-c-Myc antiserum.
To test for N-glycosylation of a4LG1–LG5 and a4LG1–LG5
in selected clones, media samples and lysates of cells grown in
the presence and absence of tunicamycin were analyzed by
SDS-gel electrophoresis followed by immunoblotting with an-
tiserum against c-Myc (Fig. 2A). Faster migration of the major
band of ;120 kDa in the presence of tunicamycin indicates
N-glycosylation of both a1LG1–LG5 and a4LG1–LG5. When
FIG. 1. Plasmids encoding a1LG1–LG5 or a4LG1–LG5 se-
quences. Map of pEFa1Gmyc and pEFa4Gmyc and the strategy of
plasmid construction are summarized. Expression was under the con-
trol of the elongation factor 1a (EF1a) promoter. The cDNA sequence
encoding mouse a1LG1–LG5 or a4LG1–LG5 was inserted between
cDNA sequences of the erythropoietin receptor (EpoR) signal sequence
for the delivery of products to the secretory pathway and c-myc for
epitope tagging. The modular structure of the G domains is schemati-
cally shown with Y-shaped symbols and letters C indicating the approx-
imate positions of N-glycosylation sites and cysteine residues,
respectively.
FIG. 2. N-Glycosylation and intrachain disulfide bonding of
a1LG1–LG5 and a4LG1–LG5. A, cells overexpressing a1LG1–LG5
(a1G) or a4LG1–LG5 (a4G) were allowed to attach to culture dishes,
washed with Dulbecco’s modified PBS and fed with fresh media with
(1) or without (2) 10 mg/ml tunicamycin. After 12 h, cell lysates (C) and
conditioned medium (M) were separated by SDS electrophoresis in 12%
acrylamide gels under reducing conditions and immunoblotted with
antiserum against c-Myc. B, conditioned medium was separated by SDS
electrophoresis in 12% acrylamide gels under non-reducing and reduc-
ing conditions and immunoblotted with antiserum against c-Myc. Posi-
tions of size markers are indicated by arrowheads.
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compared with a4LG1–LG5, the larger migration difference
observed for the tunicamycin-treated and untreated a1LG1–
LG5 might reflect the different number of potential N-glycosy-
lation sites (7 in a1LG1–LG5; 4 in a4LG1–LG5; compare Fig.
1). In contrast to the a1LG1–LG5 expressing cells, tunicamycin
treatment of the a4LG1–LG5 expressing cells nearly com-
pletely blocked a4LG1–LG5 secretion. Detection of several dis-
tinct minor bands migrating faster than the full-length LG1–
LG5 modules in the cell lysates suggests intracellular
degradation of intermediates. Some degradation was also ob-
served for the secreted proteins. Analysis of conditioned me-
dium by SDS-gel electrophoresis performed under reducing or
nonreducing conditions shows an increased mobility of the
non-reduced a4LG1–LG5, whereas the migration position of
the major part of a1LG1–LG5 remained unaffected (Fig. 2B).
This suggests a more compact configuration for the oxidized
a4LG1–LG5 due to intrachain disulfide bonds, although the
upward smear seen in the non-reduced sample could be due to
some heterogeneity. The unchanged mobility observed for most
of a1LG1–LG5 might indicate incomplete disulfide bond for-
mation; the weak band migrating faster under non-reducing
conditions might reflect a minor population with more disulfide
bonds.
High Affinity Heparin Binding Activity of a4LG1–LG5—
a1LG1–LG5 and a4LG1–LG5 were purified by heparin affinity
chromatography. Applying a linear gradient, the a1LG1–LG5
and a4LG1–LG5 eluted at salt concentrations of 300 and 470
mM, respectively, and analysis of column fractions by SDS-gel
electrophoresis showed major bands in the migration positions
of full-length G domains (Fig. 3). For both proteins, minor
bands could bee seen at positions corresponding to about 50–60
kDa which on immunoblots were recognized by a1LG1–LG5- or
a4LG1–LG5-specific antisera (not shown). Addition of phenyl-
methylsulfonyl fluoride to the medium directly after harvesting
reduced the amount of these contaminants suggesting that
serine protease(s) produced by CHO cells digested the prod-
ucts. The differential heparin affinity of such fragments as
especially observed for a4LG1–LG5 suggests that some subdo-
mains contain high and low affinity binding sites.
Binding of G domains to solid-phase heparin confirmed the
high affinity of the a4 G domain (Fig. 4). Serially diluted
a1LG1–LG5 or a4LG1–LG5 was incubated with heparin bound
to the surface of multiwell plates. The concentrations required
for half-maximal binding determined with specific antisera
were 14 and 1.4 nM for a1LG1–LG5 and a4LG1–LG5, respec-
tively. Antiserum against the c-Myc tag resulted in the same
values confirming that the higher affinity of a4LG1–LG5 was
not due to different titers of antisera. The half-maximal con-
centration determined for a1LG1–LG5 is in the same range as
previously reported (19). When the same experiments were
performed in the presence of 5 mM Ca21, no measurable
changes for heparin affinity were observed for a4LG1–LG5
(data not shown).
Characterization of Heparin Binding Activity of a4LG1–
LG5—The results in Fig. 5 show that N-glycan in a4LG1–LG5
is not essential for its high affinity binding to heparin. To
remove N-linked carbohydrates, a4LG1–LG5 was treated with
PNGase F. When analyzed by gel electrophoresis, more than
80% of the product migrated in a comparable position as the
intracellular precursor produced in the presence of tunicamy-
cin (Fig. 5A). Despite the extensive digestion of N-glycans,
a4LG1–LG5 retained its high affinity to solid-phase heparin
indicating that this activity is not mediated by carbohydrates
(Fig. 5B).
To determine whether the heparin binding activity depends
on the native structure of a4LG1–LG5, de- and renaturation
experiments with urea were performed. Three heparin columns
FIG. 4. Binding of a1 and a4 G domains to solid-phase heparin.
Binding of serially diluted a1LG1–LG5 or a4LG1–LG5 to solid-phase
heparin-BSA coated to the surface of multi-well plates was detected by
antisera against a1LG1–LG5 (anti-a1G), a4LG1–LG5(anti-a4G), or
Myc tag (anti-myc).
FIG. 3. Purification of a1LG1–LG5
and a4LG1–LG5 by heparin columns.
Conditioned medium (about 500 ml) of
CHO cells expressing a1LG1–LG5 or
a4LG1–LG5 was applied to a 5-ml hepa-
rin column, the column was washed and
eluted with a NaCl gradient (dashed line
in A and C). The protein elution profile as
determined by the BCA assay (closed cir-
cles) and SDS gels stained with Coomas-
sie Brilliant Blue of column fractions are
shown for a1LG1-LG5 (A and B) or
a4LG1-LG5 (C and D). Fraction numbers
are given at the top of the gels. Molecular
weight markers (lane M) and their size
are shown on the left.
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A, B, and C were loaded with equal amounts of protein (Fig. 6).
While column A was left under native conditions, columns B
and C were washed with 8 M urea. Column C was then washed
with a buffer without urea. All three columns were then eluted
with a 0 to 800 mM NaCl gradient in the absence (columns A
and C) or presence (column B) of 8 M urea. Gel electrophoresis
of the column fractions showed that heparin binding activity
was reduced to about 180 mM NaCl for column B, but could be
nearly completely recovered by the renaturation step used on
column C. Although denaturation of a4LG1–LG5 substantially
lowers the affinity, it is important to note that the denatured
a4LG1–LG5 showed the affinity to heparin.
High and Low Affinity Heparin Binding Subdomains in the
a4 G Domain—Endogenous protease(s) of CHO cells appeared
to partially degrade a4LG1–LG5 resulting in fragments with
different affinity for heparin (Fig. 3D). Since this suggests
multiple binding sites of different affinity, we tried to dissect
a4LG1–LG5 by proteolytic digestion. Both chymotrypsin and
trypsin applied at enzyme/substrate ratios of 1/50 for 2 h con-
verted most of the intact a4LG1–LG5 into discrete fragments of
35–45 kDa as determined by SDS electrophoresis. At higher
enzyme/substrate ratios, additional smaller fragments could be
found. After loading chymotrypsin-digested a4LG1–LG5 on a
heparin column equilibrated in 150 mM NaCl, most protein
appeared in the flow-through (Fig. 7A). Elution with a salt
gradient removed two major species at ;330 and ;480 mM
NaCl, respectively. SDS electrophoresis of peak 1 showed a
single band of 41 kDa whereas peak 2 showed two bands of 44
and 39 kDa (left panel in Fig. 7B). Sequencing of the 41-kDa
band resulted in TQSRAAS corresponding to a start at residue
1037 suggesting that this fragment contains LG2 and LG3
modules (Fig. 9). Sequencing of the 44- and 39-kDa bands gave
the identical sequence KFLEQKE corresponding to a start at
residue 1437 which is within a hinge region connecting the LG3
and LG4 modules (Fig. 9). Both fragments thus contain the
entire LG4 subdomain. Since the 44-kDa fragment was recog-
nized by anti-c-Myc antiserum (right panel in Fig. 7B), it covers
FIG. 5. Effect of N-glycan digestion on heparin binding of
a4LG1–LG5. A, a4LG1–LG5 was treated with PNGase F and sepa-
rated by SDS-gel electrophoresis under reducing condition together
with the untreated protein and lysates of cells cultured in the presence
or absence of tunicamycin. a4LG1–LG5 was detected by immunoblot-
ting using specific antiserum. B, the binding activity of control and
PNGase F-treated a4LG1–LG5 to solid-phase heparin was determined
as described in the legend to Fig. 4 using antiserum against the Myc
tag.
FIG. 6. Effect of de- and renaturation of a4 G domain on hep-
arin binding activity. Three heparin columns (A, B, and C) were
loaded with purified a4LG1–LG5. Column A was washed with buffer B
whereas columns B and C were washed with buffer B containing 8 M
urea. Columns A and C were then washed with 3 ml of buffer B while
column B was washed with 3 ml of buffer B containing 8 M urea.
Columns were eluted with a 0–800 mM NaCl gradient in buffer B which
for column B contained 8 M urea. Gels of fractions from column B show
somewhat lower staining intensity which might be due to a lower
efficiency of trichloroacetic acid precipitation in the presence of urea.
FIG. 7. High and low affinity heparin binding a4 G chymotryp-
tic fragments. A, a4LG1–LG5 was partially digested with chymotryp-
sin (enzyme/substrate ratio, 1:50, 37 °C, 2 h) and the digest was applied
to a heparin column. Bound protein eluted in two peaks corresponding
to an ionic strength of 330 and 480 mM. Closed circles and dotted line
indicate protein and estimated NaCl concentrations, respectively. B,
peak 1 and peak 2 fractions were analyzed by SDS-gel electrophoresis
and stained with Coomassie Brilliant Blue, or were immunoblotted
with antiserum against a synthetic peptide of a4LG5 module (anti-
a4LG5 peptide) or the c-Myc tag (anti-c-myc).
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the sequence down to the C terminus of G domain. The 39-kDa
fragment reacted with antiserum against a synthetic peptide
LDESFNIGLKFEIA1665 (middle panel in Fig. 7B) located
close to the N terminus of the LG5 module (Fig. 9), but not with
anti-Myc (right panel in Fig. 7B). The size of this fragment
suggests that it covers the LG4 module and about 80–90% of
the LG5 module (Fig. 9). Despite that the exact cleavage sites
were different, parallel analysis of tryptic digests gave quite
similar results: two peaks were eluted from the heparin column
with one (45 kDa) and two (40 and 35 kDa) bands detected in
these peaks. The low and high affinity fragments covered LG2–
LG3 and LG4–LG5 modules, respectively (data not shown).
To narrow down the identity of the high affinity binding site,
a4LG1–LG5 was bound to heparin beads and extensively di-
gested with trypsin. The heparin bound form was chosen to
protect the active configuration. Two fragments of 35 and 23
kDa could be eluted at an ionic strength of about 370–400 mM
NaCl (Fig. 8A). Both fragments did not react with anti-c-Myc,
but they were recognized by anti-a4LG1–LG5 antiserum (Fig.
8B). Sequencing of both fragments gave identical N termini of
AIEHAYQ corresponding to a start at residue 1457 which is
about the begin of LG4 module (Fig. 9). Since the 23-kDa
fragment was negative to antiserum against the a4LG5 peptide
(Fig. 8B), it seems to cover the entire LG4 module and perhaps
some residues of the LG5 module (Fig. 9). Thus, the 23-kDa
fragment was the shortest fragment preserving the high affin-
ity heparin-binding site of a4LG1–LG5. The elution of this
fragment from the heparin column at a slightly lower NaCl
concentration than that observed for the longer fragments ex-
tending more into the LG5 subdomain (Fig. 7) suggests that the
sequence within LG5 can support the LG4-binding site.
Competition of Synthetic Peptides within a4LG4 Module for
Heparin Binding—To further specify the high affinity heparin-
binding site, a series of 24 overlapping 12-mer synthetic pep-
tides were synthesized which cover the sequence region of
residues 1450 to 1651 including the entire LG4 module (Fig.
10A). Peptides (;200 mM) were added to a mixture of a4LG1–
LG5 (;0.4 mM) and heparin-coated beads to find which se-
quence can compete for the binding of a4LG1–LG5 to heparin.
As some peptides (see asterisks in Fig. 10A) were insoluble in
aqueous solvent, they were omitted from the assay. Except for
peptide A4G–93, none of them contains any basic residue and
thus they are unlikely to cover a heparin-binding site. Only
peptide A4G–82 was able to strongly compete for heparin bind-
ing with a4LG1–LG5, although A4G-83 showed some weak
activity (Fig. 10B). This suggests that two basic amino acids
(His1518 and Arg1520) in the sequence TLFLAHGRLVFM1524
are important for the high affinity binding of the a4 G domain.
FIG. 9. Regions of a4LG1–LG5 contained in chymotryptic and
tryptic fragments. The N-terminal sequences and estimated sizes of
the chymotryptic and tryptic fragments of are shown aligned to sche-
matic modular structure of a4LG1–LG5 with triangles indicating the
approximate positions of N-glycosylation sites and cysteine residues.
The positions of 12 cysteine residues and their estimated disulfide
bondings are indicated at the bottom.
FIG. 10. Competition of synthetic peptides with a4LG1–LG5
for heparin binding. A, a series of overlapping peptides covering
a4LG4 module were synthesized. A4G-82S and -82T contain the same
residues as peptide A4G-82 but in scrambled order. The two cysteine
residues of the a4LG4 sequence which would be located between A4G-
93/94 and A4G-95/96 were omitted. Asterisks denote peptides that were
insoluble in aqueous solution. B, a4LG1–LG5 (;0.4 mM), peptides
(;200 mM), and heparin-coated beads were incubated for 1 h at 4 °C,
washed, and eluted with SDS sample buffer which was analyzed by gel
electrophoresis followed by staining with Coomassie Brilliant Blue. A
control sample without peptide is shown in the left lanes (2). C, the
a4LG4 sequence environment of peptide A4G-82 is shown aligned to the
mouse a2LG5 module (a2LG5) which high resolution structure has
been solved (21). The position of b2strands D to G of a2GL5 is indicated
by boxes. Basic and acidic residues of a4LG4 are highlighted by dots and
triangles, respectively.
FIG. 8. High affinity heparin-binding site in a4LG4 module. A,
a4LG1–LG5 was bound to a heparin column and digested with trypsin
(2 h, 37 °C), eluted with a NaCl gradient from 150 to 600 mM, and 1-ml
fractions were collected. Fractions 18–20, corresponding to about 370–
400 mM salt, were analyzed by Tricine electrophoresis, and the gel was
stained with Coomassie Brilliant Blue. B, immunoblots using anti-
serum against the c-Myc tag (myc), the synthetic peptide of a4LG5
(peptide) and a4LG1–LG5 (a4G) are shown.
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The inactivity of peptides A4G-82S and -82T consisting of the
same amino acids but in a randomly scrambled order indicates
the significance of the specific positioning and context of these
basic residues. When the peptide concentration was reduced to
;20 mM, the competitive effect of A4G-82 was hardly detecta-
ble. This indicates that a more than 50-fold molar excess of
peptide was needed to bind to heparin at efficiency comparable
to that of a4LG1–LG5.
Heparin Binding Activity of Recombinant a4LG4 Module
Having Mutation at His1518 or Arg1520—To confirm the critical
role of basic amino acids in peptide A4G-83, we produced a GST
fusion protein of a4LG4 module in E. coli by constructing a
pGEX plasmid harboring cDNA encoding the sequence from
Ser1452 through Pro1636 with mutation of none, R1518A, or
H1520A. pGEX was our choice to extract the product from
bacteria by sonication. When the extract from the clone pro-
ducing wild type a4LG4 fusion protein was applied to a heparin
column, one-half of the protein was detected in unbound frac-
tion probably due to overloading, but the least was eluted at
NaCl concentration of 400–500 mM (Fig. 11). GST sequence
alone showed no affinity to heparin (Fig. 11). This showed that
the bacterial system could produce the a4LG4 module with
similar configuration as in the CHO system. The affinity was
comparable to the 44- and 39-kDa fragments (Fig. 7) but was
higher than the 35- and 23-kDa fragment (Fig. 8), suggesting
that Arg1456 may contribute to heparin binding. Mutation of
R1518A reduced the affinity and the protein was eluted at
NaCl concentrations of 100–200 mM (Fig. 11). Mutation of
H1520A showed a more dramatic effect and almost totally
ruined the affinity of the a4LG4 module (Fig. 11). We thus
found that the sequence of AHGRL1521 was critical for heparin
binding.
DISCUSSION
When compared with other laminin G domains so far studied
(15–21), a4 G domain shows the highest affinity to heparin.
a4LG1–LG5 eluted from a heparin column at a NaCl concen-
tration of 470 mM (Fig. 3C) whereas different LG modules of a1
and a2 chains, and the whole a1 G domain were eluted at an
ionic strength of 140–360 mM (15, 17, 19). The a1LG1–LG5
prepared by us also eluted at 300 mM NaCl (Fig. 3A). In a solid
phase binding assay using immobilized heparin, the concentra-
tions of a4LG1–LG5 and a1LG1–LG5 required for half-maxi-
mal binding were 1.4 and 14 nM, respectively (Fig. 4). For the
a1 G domain, this value is in the same range as reported for
various a1 and a2 LG modules (19). The half-maximal concen-
tration of 3 nM reported recently for a5LG4–LG5 (21) was yet
higher than we found for a4LG1–LG5. The affinity of a4 G
domain is comparable to that found for the high affinity hepa-
rin binding type III repeats in fibronectin (41) and for the
heparin-binding region present within the triple helical part of
the collagen a1(V) chain (42), but lower than the extremely
high affinity of lipoprotein lipase (43) and antithrombin III
(44). The physiological significance of this high affinity of a4 G
domain remains unclear. In laminins containing the full size a
chains (a1 and a2), further heparin-binding sites have been
mapped to the N-terminal domain (45). As these regions are
absent in the truncated a3 (2) and a4 chains (27, 29, 30, 33), an
enhanced affinity to heparan sulfate proteoglycans at the C
termini might produce a basement membrane architecture dif-
ferent from that suggested for the laminins containing the
full-size laminin chains (46).
As shown for a1 G domain (15, 16), trypsin and chymotrypsin
digestion of a4LG1–LG5 produced fragments with differential
affinity to heparin. Our fragments of low affinity eluting at 330
mM NaCl consisted of LG2–LG3 modules; the high affinity
fragments eluting at 480 mM NaCl contained LG4–LG5 mod-
ules (Fig. 7). Extensive digestion into the LG4 module slightly
reduced its affinity (Fig. 8), but it still retained high affinity
comparable to the whole a4LG1–LG5. This indicates that the
binding sites are independent and do not cooperate to enhance
the affinity to heparin. This is different from the heparin-
binding site of antithrombin III, where seven lysine and argi-
nine residues line a 50-Å cannel supported by the whole struc-
ture of the molecule (44). In that situation, the key residues can
cooperate with each other to produce extremely high affinity
requiring 2 M NaCl to be eluted from a heparin column. Diges-
tion of a4LG1–LG5 with PNGase F did not alter the affinity to
heparin (Fig. 5B). Considering that all putative N-glycosylation
sites are within LG2–LG3 modules (Fig. 9), however, this does
not prove that N-glycans are dispensable. Since the affinity of
the whole a4LG1–LG5 was determined by the most potential
site located within the LG4 module, there remains a possibility
that binding of the LG2–LG3 low affinity site to heparin might
be affected by the digestion but binding of the whole molecule
was supported by the high affinity site within LG4 module.
Treatment of a4LG1–LG5 with 8 M urea reversibly dimin-
ished its heparin binding activity (Fig. 6), indicating that bind-
ing depends on the local configuration despite the independ-
ence of individual binding sites. Since the binding activity
could be recovered to the high affinity exerted mainly by LG4
module after withdrawal of urea, the effect of denaturation/
renaturation on the binding activity of whole a4LG1–LG5 was
expected to reflect the configuration of LG4 module. Notably,
weak but distinct affinity to heparin was even retained in the
presence of 8 M urea (Fig. 6B), suggesting that some affinity is
independent of the correct tertiary structure. Based on these
observations, we tested the competition of a series of overlap-
ping synthetic peptides covering the entire LG4 sequence for
the binding with a4LG1–LG5 to heparin beads. Surprisingly,
peptide A4G-82 containing only two basic residues, His1518 and
Arg1520, specifically competed for binding whereas peptides
containing two large basic clusters, namely Lys1492-Arg1494-
His1497 in A4G-79 and His1529-Lys1530-Lys1531-Lys1533 in A4G-
84, did not show any activity (Fig. 10B). Site-directed mutagen-
esis of the sequence by producing GST fusion proteins of the
a4LG4 module in E. coli confirmed the critical role of His1518
and Arg1520 (Fig. 11). Alignment of a4LG4 sequence with that
of the a2LG5 module (Fig. 10C) suggests that the peptide
A4G-82 sequence relates to the turn between strands E and F
FIG. 11. Heparin binding activity of GST fusion protein of
a4LG4 module having mutation of R1518A or H1520R. GST fusion
protein of a4LG4 (GST-a4LG4), its mutant of R1518A (GST-a4LG4(R/
A)), of H1220A (GST-a4LG4(H/A)) or GST was extracted from E. coli of
the corresponding clone and loaded to a heparin-Sepharose column.
After washing with a buffer containing 10 mM Tris-HCl (pH 7.4) and 2
mM EDTA, the column was eluted stepwise by the same buffer contain-
ing the indicated concentration of NaCl. 10 ml of the fractions was
separated by SDS electrophoresis using 12% acrylamide gel and the
proteins were detected by immunoblot with antiserum against
a4LG1–5 or GST.
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in the recently determined a2LG5 structure (22). Thus, His1518
and Arg1520 would be extruded at the opposite edge of the
14-stranded b-sheet sandwich structure to where a calcium ion
binds. The neighboring basic cluster of His1529 to Lys1533 rep-
resented by peptide A4G-84 would correspond to the turn con-
necting strands F and G (Fig. 10C) close to the calcium ion
coordinating center in a2LG5 (20). The a4LG4 module contains
a cluster of acidic amino acids Asp1506-Glu1508-Glu1509-Asp1511
which matches to the turn between strands D and E (Fig. 10C)
and would be extruded to the calcium ion binding edge. In our
solid-phase binding assay, measurements of the heparin affin-
ity of the a4 G domain showed identical results in the presence
and absence of 5 mM Ca21. The a4LG4 high affinity site for
heparin binding is thus opposite to the edge responsible for the
interaction with calcium ion, heparin, and a-dystroglycan in
a2LG5 (20).
A 500-fold concentration of A4G-82 was needed to observe
the competition. This suggested that only a small part of the
A4G-82 peptide had the correct configuration of the heparin-
binding site. Alternatively, some additional sequence motif ad-
jacent to the E-F turn might be needed for the high affinity
heparin binding. The crystal structure of the a2LG5 module
predicts that another basic amino acid cluster of Lys1492-
Arg1494-His1497 at the N terminus of the strand D (Fig. 10C)
might be adjacent to F-G turn. Although the peptide represent-
ing this cluster (A4G-79) alone did not show competitive effect
(Fig. 10B), we could expect that Lys1492-Arg1494-His1497 would
cooperate with His1518-Arg1520 to organize a high affinity hep-
arin-binding site. Combination of A4G-82 and A4G-79 in the
competition assay, however, did not show any synergetic effect
on the competition activity of A4G-82 (data not shown).
Crystal structure of the a2LG4 and LG5 module pair showed
that the extended N-terminal sequence (the linker sequence
between LG3 and LG4 modules) is disulfide bonded to the LG5
module and the paired modules are arranged in a V-shaped
fashion related by a 110° rotation to locate two calcium-binding
sites 65 Å apart at the tips of the domains opposite the polypep-
tide termini (23). Because of this extra disulfide bonding, LG5
is likely to be closer in space to the LG1–LG3 portion than LG4.
LG4 might be thus extruded from the main body of G domain.
Although the edge opposite the calcium ion-binding site comes
to the bottom of V-shape arrangement of the modules, the E-F
turn is exposed outside of the contacting interface. Thus, the
high affinity heparin-binding site suggested in a4LG4 might be
located at the tip of entire laminin molecule for facilitated
access to other extracellular matrix components. When over-
lapped on a4G4 sequence, the extra disulfide bonding fond in
a2LG4-LG5 pair correspond to a bonding between Cys1449 and
Cys1719 (7th and 10th cysteines in Fig. 9). It is intriguing that
the 39-kDa fragment in chymotrypsin disgusts (Fig. 7) con-
tained this putative disulfide bonding whereas the shortest
fragments of 35 and 23 kDa in trypsin digests of a4LG1–LG5
bound to heparin (Fig. 8) did not (Fig. 9). Reduced affinity of the
latter fragments suggests that the extra disulfide bonding is
also important for heparin binding by combining the N-termi-
nal half of LG5 to LG4 module.
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